Talkspace (TALK) reported $229M in revenue for fiscal 2025, +22.0% year on year. That ranks #2615 by revenue among 2853 SEC filers and #274 in Healthcare. Net income was $7.8M, a net margin of 3.4%. Revenue has grown 34.8% a year on average since 2019 ($38.2M then). The fiscal 2025 balance sheet shows $135M in total assets, $37.4M in cash and $300,000 in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $229M | +22.0% | FY20252025-12-31 |
| Gross profitGrossProfit | $85.8M | +15.4% | FY20242024-12-31 |
| Operating incomeOperatingIncomeLoss | $3.2M | +$7.6M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $7.8M | +578.8% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $8.5M | −24.4% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $151,000 | −56.9% | FY20232023-12-31 |
| Total assetsAssets | $135M | −2.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $117M | −0.3% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $37.4M | −51.3% | FY20252025-12-31 |
| Long-term debtLongTermDebtAndCapitalLeaseObligations | $300,000 | — | FY20222022-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $61.7M | −$6.3M | Open → |
| Q2 20262026-06-30 | $61.7M | −$1.5M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Talkspace, Inc.
- Ticker
- TALK
- Exchange
- Nasdaq
- SIC classification
- Services-Health Services (8000)
- Fiscal year end
- 12-31
- CIK
- 0001803901
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 11, 2026Open filing →
- 10-KMar 13, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Akebia TherapeuticsAKBA | $236M | −$5.3M |
| AnaptysbioANAB | $235M | −$13.2M |
| CerusCERS | $234M | −$15.6M |
| TalkspaceTALK | $229M | $7.8M |
| LifevantageLFVN | $229M | $9.8M |
| Puma BiotechnologyPBYI | $228M | $31.1M |
| AxogenAXGN | $225M | −$15.7M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Talkspace — Key figures |url=https://companiesranked.com/en/company/talkspace |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Talkspace — Key figures. CompaniesRanked. https://companiesranked.com/en/company/talkspaceBibTeX
@misc{companiesranked-en-company-talkspace-2026,
author = {{CompaniesRanked}},
title = {{Talkspace — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/talkspace}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-105146 · March 13, 2026
{{cite web |title=Talkspace — Key figures — 10-K (0001193125-26-105146) |url=https://www.sec.gov/Archives/edgar/data/1803901/000119312526105146/talk-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-13}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.